Company profile for Cullgen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

To utilize our revolutionary and proprietary targeted protein degradation technology to create, in a highly efficient manner, new drugs for treatment of diseases that currently lack effective therapies. Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our pro...
To utilize our revolutionary and proprietary targeted protein degradation technology to create, in a highly efficient manner, new drugs for treatment of diseases that currently lack effective therapies. Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our proprietary technology platform, uSMITE™, based on recent advances in the science of protein degradation. Typically, drugs are designed to interact with the functional sites of proteins and block their activities.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
12671 High Bluff Drive - Suite 130, San Diego, California 92130
Telephone
Telephone
+1 -858-284-0115
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/18/3152268/0/en/Cullgen-Completes-Enrollment-in-Phase-1-Trial-of-its-Novel-Non-Opioid-Pain-Product-Candidate-CG001419.html

GLOBENEWSWIRE
18 Sep 2025

https://www.globenewswire.com/news-release/2025/01/22/3013421/0/en/Cullgen-Begins-Phase-1-Dosing-of-its-Potential-First-in-Class-Oral-Pan-TRK-Protein-Degrader-for-Acute-and-Chronic-Pain.html

GLOBENEWSWIRE
22 Jan 2025

https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-announce-proposed-merger-302303818.html

PR NEWSWIRE
13 Nov 2024

https://www.businesswire.com/news/home/20240116086836/en

BUSINESSWIRE
16 Jan 2024
Astellas pays Cullgen $35M upfront to form protein degrader pact
Astellas pays Cullgen $35M upfront to form protein degrader pact

16 Jun 2023

// Nick Paul Taylor FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/astellas-adds-cullgen-parade-protein-degrader-pacts-paying-35m-upfront-access-tech

Nick Paul Taylor FIERCE BIOTECH
16 Jun 2023

https://www.businesswire.com/news/home/20230508005341/en

BUSINESSWIRE
08 May 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty